R&D Timeline
QR-01
QR-01 is a product that not only introduces a novel active compound for this disorder, but also employs a unique formulation. The formulation is a proprietary liquid at administration but becomes semi-solid at mouth temperature.
In addition, the active molecule is synthesized by a novel proprietary method of synthesis.
Animal studies
The Company has currently successfully completed a 14-day toxicology study in hamsters and test of effectiveness in a Beagle Dog Study.
Q1 2025:
14-day toxicology
study in hamsters
In the 14-days toxicology study, all animals exhibited high tolerance to the drug, with no adverse reactions or irritation at the buccal application site. No significant side effects were observed and more importantly, the necroscopic cross examination showed no changes in tissues. The successful completion of this study marks an important milestone for Orocidin, providing the foundation for the upcoming pivotal 8-week toxicity study.
The Company launched an extended eight-week study to further confirm its safety.
Q2 2025:
Efficacy study
in beagle dogs
The Beagle Dog Study is the first study that shows Orocidin’s drug, QR-01, having a direct effect on periodontitis diagnosed in beagle dogs.
The 13-day small efficacy study was conducted on beagle dogs with clinically confirmed periodontitis.
The dogs demonstrated consistent improvements across key clinical endpoints, including the Gingival Index, the Plaque Index and overall periodontal Disease.
These results support the clinical relevance of QR-01, as periodontitis in dogs is a well-established model for the human condition.
Moreover, QR-01 was well tolerated, with no adverse side effects reported throughout the treatment period.
Q3 2025:
Studies in
Wister rats
Pre-clinical efficiacy study in Wistar rats withperiodonitits (ongoing).
Q1 2026:
Studies in Wistar
rats and hamsters
Initiate 8-Week toxicity study in hamsters.
Q3 2026:
Pilot study
in patients
Initiate pilot efficacy study
in patients.